Asia-Pacific solid tumors market to reach $2.3 billion by 2019
The Asia-Pacific solid tumors treatment markets - bladder, ovarian, pancreatic and prostate cancers - is expected to increase from a value of $1 billion in 2012 to $2.3 billion in 2019, at a compound annual growth rate (CAGR) of 12.3%, according to a new report added to the offering of researchandmarkets.com, titled Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies.
According to the report, the fastest growing market for solid tumors in the Asia-Pacific region is Australia, achieving an expected CAGR of 13.9% by the end of the forecast period. A slower growth rate is expected in India (9.7%) and China (5.5%), due primarily to stricter pricing regulations and recent price cuts.
Average treatment cost expected to grow
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze